WallStreetZenWallStreetZen

NASDAQ: NXL
Nexalin Technology Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their NXL stock forecasts and price targets.

Forecast return on equity

Is NXL forecast to generate an efficient return?

Company
N/A
Industry
20.51%
Market
135.74%

Forecast return on assets

Is NXL forecast to generate an efficient return on assets?

Company
N/A
Industry
10.91%

NXL earnings per share forecast

What is NXL's earnings per share in the next 1 years based on estimates from 2 analysts?

Avg 1 year Forecast
-$0.39

NXL revenue forecast

What is NXL's revenue in the next 2 years based on estimates from 2 analysts?

Avg 1 year Forecast
$348.5k+15.52%
Avg 2 year Forecast
$696.9k+131.03%
NXL's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

NXL revenue growth forecast

How is NXL forecast to perform vs Medical Devices companies and vs the US market?

Company
15.52%
Industry
8.97%
Market
170.38%
NXL's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
NXL's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

NXL vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
NXL$0.38N/AN/A
NVNO$10.50N/AN/A
TNON$0.78N/AN/A
BMRA$2.19N/AN/A
HSCS$1.99$8.00+302.01%Buy
View Top Medical Device Stocks

Nexalin Technology Stock Forecast FAQ

What is NXL's earnings growth forecast for 2026-2026?

(NASDAQ: NXL) Nexalin Technology's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Devices industry's average forecast earnings growth rate of 53.95%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 1,428.47%.

Nexalin Technology's earnings in 2026 is -$8,222,181.

In 2026, NXL is forecast to generate -$8,107,110 in earnings, with the lowest earnings forecast at -$7,866,305 and the highest earnings forecast at -$8,428,184.

If you're new to stock investing, here's how to buy Nexalin Technology stock.

What is NXL's revenue growth forecast for 2026-2027?

(NASDAQ: NXL) Nexalin Technology's forecast annual revenue growth rate of 15.52% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.97%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 170.38%.

Nexalin Technology's revenue in 2026 is $301,647.On average, 2 Wall Street analysts forecast NXL's revenue for 2026 to be $7,171,675, with the lowest NXL revenue forecast at $6,958,655, and the highest NXL revenue forecast at $7,455,701.

In 2027, NXL is forecast to generate $14,343,349 in revenue, with the lowest revenue forecast at $13,917,309 and the highest revenue forecast at $14,911,403.

What is NXL's forecast return on assets (ROA) for 2026-2027?

(NASDAQ: NXL) forecast ROA is N/A, which is lower than the forecast US Medical Devices industry average of 10.91%.

What is NXL's Earnings Per Share (EPS) forecast for 2026-2026?

(NASDAQ: NXL) Nexalin Technology's current Earnings Per Share (EPS) is -$0.50. In 2026, NXL's EPS is forecast to hit -$0.39 (min: -$0.38, max: -$0.41).

What is NXL's forecast return on equity (ROE) for 2026-2027?

(NASDAQ: NXL) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.